MetLife Investment Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.99M Sell
35,601
-1,055
-3% -$263K 0.04% 431
2025
Q4
$8.83M Sell
36,656
-1,298
-3% -$332K 0.04% 399
2025
Q3
$10.4M Sell
37,954
-968
-2% -$264K 0.05% 351
2025
Q2
$10M Sell
38,922
-923
-2% -$220K 0.06% 312
2025
Q1
$8.92M Sell
39,845
-733
-2% -$171K 0.05% 371
2024
Q4
$9.28M Buy
40,578
+593
+1% +$143K 0.05% 285
2024
Q3
$9.76M Sell
39,985
-1,010
-2% -$226K 0.06% 264
2024
Q2
$7.85M Buy
40,995
+593
+1% +$120K 0.05% 307
2024
Q1
$8M Sell
40,402
-1,247
-3% -$228K 0.05% 293
2023
Q4
$7.16M Sell
41,649
-703
-2% -$108K 0.05% 314
2023
Q3
$6.26M Sell
42,352
-952
-2% -$172K 0.05% 323
2023
Q2
$9.46M Sell
43,304
-321
-0.7% -$71.5K 0.07% 233
2023
Q1
$9.55M Sell
43,625
-340
-0.8% -$73.8K 0.07% 222
2022
Q4
$9.15M Sell
43,965
-855
-2% -$188K 0.07% 227
2022
Q3
$9.78M Sell
44,820
-466
-1% -$106K 0.08% 196
2022
Q2
$9.49M Sell
45,286
-249
-0.5% -$53K 0.07% 210
2022
Q1
$11M Buy
45,535
+13,339
+41% +$3.23M 0.07% 213
2021
Q4
$8.39M Sell
32,196
-671
-2% -$174K 0.07% 231
2021
Q3
$8.66M Sell
32,867
-870
-3% -$238K 0.08% 210
2021
Q2
$8.32M Sell
33,737
-937
-3% -$197K 0.07% 226
2021
Q1
$6.73M Sell
34,674
-520
-1% -$104K 0.06% 280
2020
Q4
$7.48M Sell
35,194
-1,545
-4% -$308K 0.07% 238
2020
Q3
$6.3M Sell
36,739
-1,097
-3% -$203K 0.07% 255
2020
Q2
$7.26M Buy
37,836
+773
+2% +$126K 0.08% 202
2020
Q1
$5.46M Sell
37,063
-1,134
-3% -$181K 0.07% 223
2019
Q4
$5.92M Sell
38,197
-901
-2% -$130K 0.06% 287
2019
Q3
$5.28M Sell
39,098
-427
-1% -$55.9K 0.06% 310
2019
Q2
$4.82M Sell
39,525
-1,206
-3% -$134K 0.05% 365
2019
Q1
$4.23M Sell
40,731
-18
-0% -$1.86K 0.05% 417
2018
Q4
$4.64M Sell
40,749
-771
-2% -$82.6K 0.06% 314
2018
Q3
$4.79M Sell
41,520
-499
-1% -$54.7K 0.05% 378
2018
Q2
$4.35M Sell
42,019
-993
-2% -$100K 0.05% 371
2018
Q1
$4.24M Sell
43,012
-894
-2% -$84.5K 0.05% 403
2017
Q4
$3.72M Buy
+43,906
New +$3.63M 0.04% 509

Other funds holding RMD

MetLife Investment Management's RMD Position: Q1 2026 in Review

MetLife Investment Management reduced its ResMed (RMD) stake by 2.9% in Q1 2026, selling an estimated $263K and leaving 35,601 shares worth $7.99M. The position accounts for 0.04% of the portfolio, ranked #431.

MetLife Investment Management first reported a position in RMD in Q4 2017 and has held it in 34 quarters since. The position peaked at $11M in Q1 2022. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • MetLife Investment Management held 35,601 shares of ResMed worth $7.99M as of Q1 2026.
  • MetLife Investment Management sold 1,055 ResMed shares in Q1 2026, an estimated $263K.
  • ResMed made up 0.04% of MetLife Investment Management's portfolio in Q1 2026, its #431 holding.
  • MetLife Investment Management first reported a position in ResMed in Q4 2017 and has held it in 34 quarters since.
  • MetLife Investment Management's ResMed position peaked at $11M in Q1 2022.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.